The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Open accessAbstract
Disease Overview: Diffuse large B‐cell lymphoma (DLBCL) is the most common type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes that are differentially characterized by clinical features, cell of origin (COO), molecular features, and most recently, frequently recurring mutations. Diagnosis: DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan‐B‐cell antigens, such as CD20 and CD79a. COO is determined by immunohistochemical stains, while molecular features such as double‐hit or triple‐hit disease are determined by fluorescent in situ hybridization analysis. Commercial tests for frequently recurring mutations are currently not routinely used to inform treatment. Risk Stratification: Clinical prognostic systems for DLBCL, including the rituximab International Prognostic Index, age‐adjusted IPI, and NCCN‐IPI, use clinical factors for the risk stratification of patients, although this does not affect the treatment approach. Furthermore, DLBCL patients with non‐germinal center B‐cell (GCB)‐like DLBCL (activated B‐cell like and unclassifiable) have a poorer response to up‐front chemoimmunotherapy (CI) compared to patients with GCB‐like DLBCL. Those with c‐MYC‐altered disease alone and in combination with translocations in BCL2 and/or BCL6 (particularly when the MYC translocation partner is immunoglobulin) respond poorly to up‐front CI and salvage autologous stem cell transplant at relapse. Risk‐Adapted Therapy: This review will focus on differential treatment of DLBCL up‐front and at the time of relapse by COO and molecular features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.-Y., Harousseau, J.-L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332305 · Cited by 2,439
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Genetic and functional drivers of diffuse large B cell lymphoma
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001
Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Zhou, Z., Sehn, L. H., Rademaker, A. W., Gordon, L. I., LaCasce, A. S., Crosby-Thompson, A., Vanderplas, A., Zelenetz, A. D., Abel, G. A., Rodriguez, M. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-524108 · Cited by 930
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 748
Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679
Aukema, S. M., Siebert, R., Schuuring, E., van Imhoff, G. W., Kluin-Nelemans, H. C., Boerma, E.-J., & Kluin, P. M. (2011) · Blood · doi:10.1182/blood-2010-09-297879 · Cited by 678
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2493 · Cited by 581
Cunningham, D., Hawkes, E. A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K. M., Radford, J. A., McMillan, A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60313-x · Cited by 561
Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Petrich, A. M., Gandhi, M., Jovanovic, B., Castillo, J. J., Rajguru, S., Yang, D. T., Shah, K. A., Whyman, J. D., Lansigan, F., Hernandez-Ilizaliturri, F. J., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578963 · Cited by 467
Self-citationEnnishi, D., Jiang, A., Boyle, M., Collinge, B., Grande, B. M., Ben-Neriah, S., Rushton, C., Tang, J., Thomas, N., Slack, G. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01583 · Cited by 414
Scott, D. W., Mottok, A., Ennishi, D., Wright, G. W., Farinha, P., Ben-Neriah, S., Kridel, R., Barry, G. S., Hother, C., Abrisqueta, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2383 · Cited by 405
Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R., Polikoff, J. A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392
Viardot, A., Goebeler, M.-E., Hess, G., Neumann, S., Pfreundschuh, M., Adrian, N., Zettl, F., Libicher, M., Sayehli, C., Stieglmaier, J., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651380 · Cited by 378
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., Pietronigro, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3429 · Cited by 371
Nowakowski, G. S., LaPlant, B., Macon, W. R., Reeder, C. B., Foran, J. M., Nelson, G. D., Thompson, C. A., Rivera, C. E., Inwards, D. J., Micallef, I. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5714 · Cited by 359
Ansell, S. M., Minnema, M. C., Johnson, P., Timmerman, J. M., Armand, P., Shipp, M. A., Rodig, S. J., Ligon, A. H., Roemer, M. G. M., Reddy, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00766 · Cited by 353
Gutiérrez, G., Cardesa‐Salzmann, T. M., Climent, F., González-Barca, E. M., Mercadal, S., Mate, J. L., Sancho, J., Arenillas, L., Serrano, S., Escoda, L., et al. (2011) · Blood · doi:10.1182/blood-2010-12-322362 · Cited by 334
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
Van Den Neste, E., Schmitz, N., Mounier, N., Gill, D., Linch, D., Trneny, M., Milpied, N., Radford, J., Ketterer, N., Shpilberg, O., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.213 · Cited by 306
Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70122-0 · Cited by 304
Bromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Thieblemont, C., Briere, J., Mounier, N., Voelker, H.-U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4423 · Cited by 275
Copie-Bergman, C., Cuillière-Dartigues, P., Baia, M., Briere, J., Delarue, R., Canioni, D., Salles, G., Parrens, M., Belhadj, K., Fabiani, B., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647602 · Cited by 255
Younes, A., Thieblemont, C., Morschhauser, F., Flinn, I., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J., Vermeulen, J., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 254
Staiger, A. M., Ziepert, M., Horn, H., Scott, D. W., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Szczepanowski, M., Hummel, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3660 · Cited by 221
Wang, M., Fowler, N., Wagner-Bartak, N., Feng, L., Romaguera, J., Neelapu, S. S., Hagemeister, F., Fanale, M., Oki, Y., Pro, B., et al. (2013) · Leukemia · doi:10.1038/leu.2013.95 · Cited by 203
Ott, G., Ziepert, M., Klapper, W., Horn, H., Szczepanowski, M., Bernd, H.-W., Thorns, C., Feller, A. C., Lenze, D., Hummel, M., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276766 · Cited by 202
Leonard, J. P., Kolibaba, K. S., Reeves, J. A., Tulpule, A., Flinn, I. W., Kolevska, T., Robles, R., Flowers, C. R., Collins, R., DiBella, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.2784 · Cited by 186
Herrera, A. F., Mei, M., Low, L., Kim, H. T., Griffin, G. K., Song, J. Y., Merryman, R. W., Bedell, V., Pak, C., Sun, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2740 · Cited by 185
Howlett, C., Snedecor, S. J., Landsburg, D. J., Svoboda, J., Chong, E. A., Schuster, S. J., Nasta, S. D., Feldman, T., Rago, A., Walsh, K. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13463 · Cited by 177
Czuczman, M. S., Trněný, M., Davies, A., Rule, S., Linton, K. M., Wagner-Johnston, N., Gascoyne, R. D., Slack, G. W., Brousset, P., Eberhard, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2818 · Cited by 162
Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
Trabucco, S. E., Gerstein, R. M., Evens, A. M., Bradner, J. E., Shultz, L. D., Greiner, D. L., & Zhang, H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3346 · Cited by 156
Sun, K., Atoyan, R., Borek, M. A., DellaRocca, S., Samson, M., Ma, A. W., Xu, G.-X., Patterson, T. D., Tuck, D. P., Viner, J. L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0390 · Cited by 143
Neste, E. V. D., Schmitz, N., Mounier, N., Gill, D., Linch, D., Trněný, M., Bouadballah, R., Radford, J., Bargetzi, M., Ribrag, V., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.213 · Cited by 139
Ansell, S. M., Gutierrez, M. E., Shipp, M. A., Gladstone, D. E., Moskowitz, A. J., Borello, I., Popa-McKiver, M., Farsaci, B., Zhu, L., Lesokhin, A. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.183.183 · Cited by 136
Oki, Y., Kelly, K. R., Flinn, I. W., Patel, M. R., Gharavi, R. B., Ma, A., Parker, J., Hafeez, A., Tuck, D. P., & Younes, A. (2017) · Haematologica · doi:10.3324/haematol.2017.172882 · Cited by 136
Jurczak, W. J., Zinzani, P. L., Gaïdano, G., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy056 · Cited by 132
Nastoupil, L. J., Jain, M. D., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M. A., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., et al. (2018) · Blood · doi:10.1182/blood-2018-99-114152 · Cited by 112
Wilson, W. H., Jung, S., Pitcher, B. N., Hsi, E. D., Friedberg, J. W., Cheson, B. D., Bartlett, N. L., Smith, S. E., Johnston, N. W., Kahl, B. S., et al. (2016) · Blood · doi:10.1182/blood.v128.22.469.469 · Cited by 105
Chen, J. G., Liu, X., Munshi, M., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Guerrera, M. L., Chan, G. G., Patterson, C. J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811752 · Cited by 88
Jacobson, C. A., Hunter, B. D., Armand, P. A., Kamihara, Y., Ritz, J., Rodig, S. J., Wright, K., Lipschitz, M., Redd, R. A., Maus, M. V., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117199 · Cited by 85
McPhail, E. D., Maurer, M. J., Macon, W. R., Feldman, A. L., Kurtin, P. J., Ketterling, R. P., Vaidya, R., Cerhan, J. R., Ansell, S. M., Porrata, L. F., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.190157 · Cited by 75
Johnson-Farley, N. N., Veliz, J., Bhagavathi, S., & Bertino, J. R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.981172 · Cited by 74
Dunleavy, K. M., Roschewski, M. J., & Wilson, W. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0497 · Cited by 42
Ferreri, A. J. M., Sassone, M., Zaja, F., Re, A., Spina, M., Rocco, A. D., Fabbri, A., Stelitano, C., Frezzato, M., Rusconi, C., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30016-9 · Cited by 32
Epperla, N., Maddocks, K. J., Salhab, M., Chávez, J. C., Reddy, N. M., Karmali, R., Umyarova, E. R., Bachanová, V., Costa, C. A., Glenn, M. J., et al. (2017) · Cancer · doi:10.1002/cncr.30895 · Cited by 32
Self-citationFox, L. C., Yannakou, C. K., Ryland, G. L., Lade, S., Dickinson, M. J., Campbell, B. A., & Prince, H. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061758 · Cited by 27
Zinzani, P. L., Pellegrini, C., Derenzini, E., et al. (2013) · Hematological Oncology · doi:10.1002/hon.2049 · Cited by 25
Salles, G., Duell, J., González-Barca, E. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-113399 · Cited by 16
Cited by
High-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
Lin, X., Liu, J., Chen, J., Tang, J., Huang, Z., Wang, Y., & Shi, S. (2026) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100850 · Cited by 3
Metadata
- Authors
- Liu, Y., & Barta, S. K.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2019-04-04
- Volume
- 94
- Issue
- 5
- Pages
- 604-616
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2921072067
- Cited by
- 488
- References
- 69
- FWCI
- 37.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.